
|Videos|May 18, 2017
Dr. Kumar Discusses Daratumumab in Multiple Myeloma
Author(s)Shaji K. Kumar, MD
Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab in multiple myeloma.
Advertisement
Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab (Darzalex) in multiple myeloma.
The first monoclonal antibodies have been approved for use in multiple myeloma. Daratumumab, a monoclonal antibody, binds to CD38, which is overexpressed by multiple myeloma cells.
The results seen with daratumumab have been quite striking, says Kumar. There have been 2 large phase III trials, both of which showed adding daratumumab to regularly used regimens improved progression-free survival.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5




































